Brief: AstraZeneca's Wainua Misses Phase III Primary Endpoint In Cardio-Ttransform Trial
09/07/2026 07:41
BRIEF-AstraZeneca's Wainua Misses Phase III Primary Endpoint In Cardio-Ttransform Trial July 9 (Reuters) - AstraZeneca PLC AZN.L:
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL
CARDIO-TTRANSFORM PHASE III TRIAL FOR WAINUA DID NOT MEET PRIMARY EFFICACY ENDPOINT
WAINUA GENERALLY WELL TOLERATED WITH CONSISTENT SAFETY PROFILE
NO TREATMENT EFFECT OBSERVED IN PATIENTS ON STABILISER THERAPY AT BASELINE
SUBGROUP ANALYSIS SHOWS NOMINALLY SIGNIFICANT REDUCTION IN CV EVENTS WITH WAINUA MONOTHERAPY
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains